Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
Status:
Unknown status
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
With this protocol the ALL-SZT BFM international study group wants
to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or
unrelated matched donors (MD) is equivalent to the HSCT from matched sibling donors (MSD).
to evaluate the efficacy of haematopoietic stem cell transplantation (HSCT) from mismatched
family or unrelated mismatched donors (MMD) as compared to HSCT from matched sibling donor
(MSD) and matched donor (MD).
to determine whether therapy has been carried out according to the main haematopoietic stem
cell transplantation (HSCT) protocol recommendations. The standardisation of the treatment
options during haematopoietic stem cell transplantation (HSCT) from different donor types
aims at the achievement of an optimal comparison of survival after HSCT with survival after
chemotherapy only.
to prospectively evaluate and compare the incidence of acute and chronic graft-
versus-host-disease (GvHD) after haematopoietic stem cell transplantation (HSCT) from matched
sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).